Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof

Patent metadata

Field	Value
Publication number	US-10975069-B2
Application number	US-201916426791-A
Country	US
Kind code	B2
Filing date	May 30, 2019
Priority date	Apr 1, 2014
Publication date	Apr 13, 2021
Grant date	Apr 13, 2021

Abstract

Methods and compositions for treating cancers such as pancreatic cancer and synovial sarcoma are disclosed. Compounds comprising a sigma-2 receptor-binding moiety and a ferroptosis-inducing moiety are described, such as the methanesulfonate salt of a compound of structural Formula IV,

, wherein n is an integer chosen from 1, 2, 3, 4, and 5, and R 2 is H or methyl. At least one described molecular species exhibits an IC 50 value below 5 μM against human pancreatic cancer cells in vitro. Administration of this species promoted shrinkage of pancreatic cancer tumors in a murine model system in vivo. It led to a 100% survival of experimental animals over a time course in which control therapies provided only 30% or 40% survival. Methods of synthesis of molecular species are also disclosed.

First claim

The invention claimed is:

1. The methanesulfonate salt of a comnound of structural Formula TV.

wherein n is an integer chosen from 1, 2, 3, 4, and 5, and R 2 is H or methyl.

2. The methanesulfonate salt of claim 1 , wherein n is 1 and R 2 is H.

3. The methanesulfonate salt of claim 1 , wherein n is 5 and R 2 is H.

4. A pharmaceutical composition comprising a compound of structural Formula IV

or a salt thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

5. The pharmaceutical composition of claim 4 , wherein the pharmaceutically acceptable carrier, adjuvant, or vehicle is water or saline.

6. The pharmaceutical composition of claim 4 in the form of a solution.

7. The pharmaceutical composition of claim 4 , wherein the salt is methanesulfonate.

8. The pharmaceutical composition of claim 4 , formulated for oral delivery.

9. The pharmaceutical composition of claim 4 , formulated for intraperitoneal delivery.

10. A method for treating cancer in a subject in need thereof, comprising administering to the subject in an effective amount of the pharmaceutical composition of claim 4 , wherein the cancer is chosen from pancreatic cancer, synovial sarcoma, leukemia, lung cancer, non-small cell lung cancer, colorectal cancer, ovarian cancer, renal cell carcinoma, prostate cancer, and breast cancer.

11. The method of claim 10 , wherein the cancer is pancreatic cancer.

12. The method of claim 10 , wherein the cancer is synovial sarcoma.

13. The method of claim 10 , further comprising administering an additional anticancer drug to the subject.

14. The method of claim 13 , wherein the additional anticancer drug is an immunotherapy agent.

15. The method of claim 13 , wherein the additional anticancer drug is chosen from an alkylating agent, anthracycline, antimetabolite agent, crosslinking agent, D.N.A. replication inhibitor, intercalator, microtubule disruptor, PARP inhibitor, radiomimetic agent, radiosensitizer, strand break agent, and topoisomerase II inhibitor.

16. The method of claim 13 , wherein the additional anticancer drug is chosen from aminoglutethimide, amsacrine, anastrozole, asparaginase, barasertib, beg, bicalutamide, bleomycin, buserelin, busulfan, campothecin, capecitabine, carboplatin, carmustine, chlorambucil, chloroquine, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, demethoxyviridin, dichloroacetate, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, everolimus, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, ironotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, lonidamine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, metformin, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, olaparib, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, perifosine, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, sorafenib, streptozocin, sunitinib, suramin, tamoxifen, temozolomide, temsirolimus, teniposide, testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, and vinorelbine.

17. The method of claim 13 , wherein the method further comprises administering radiation therapy.

18. The method of claim 13 , further comprising administering surgery, thermoablation, focused ultrasound therapy, cryotherapy, or any combination thereof.

Assignees

• Univ Washington

Inventors

• Hawkins William
• Mach Robert
• Spitzer Dirk
• Vangveravong Suwanna
• Van Tine Brian

Classifications

• C07D471/08

  Bridged systems · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/517

  ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title

• A61K31/496

  Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title

• C07D451/14 Primary

  containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof · CPC title